Moonlake Immunotherapeutics 8-K filings

MoonLake Immunotherapeutics reported positive topline results from its Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis, alongside its second quarter 2026 financial results.

MoonLake Immunotherapeutics has launched a public offering of 9 million shares and 1 million pre-funded warrants to raise approximately $200 million.

MoonLake Immunotherapeutics shareholders approved an amendment to the 2022 Equity Incentive Plan, increasing share availability and modifying vesting and other terms.

MoonLake Immunotherapeutics has entered into a Master Commercial Supply Agreement with Vetter Pharma International GmbH for the manufacturing of its product candidates.

MoonLake Immunotherapeutics announced a positive final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa, aligning on submission plans and label strategy, and reported Q1 2026 financial results.

MoonLake Immunotherapeutics announced positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, secured an amended $500 million debt facility with Hercules Capital, and reported 2025 financial results.

MoonLake Immunotherapeutics received positive FDA feedback, confirming a pathway for Sonelokimab's Biologic License Application in Hidradenitis Suppurativa without additional clinical trials.

MoonLake Immunotherapeutics has entered into an underwriting agreement to sell 7,142,857 Class A ordinary shares at $10.50 each, expecting gross proceeds of $75 million.

MoonLake Immunotherapeutics announced its third quarter 2025 financial results and positive new clinical data for its Nanobody Sonelokimab across multiple inflammatory disease trials.

MoonLake Immunotherapeutics announced week 16 results from its Phase 3 VELA-1 and VELA-2 trials for sonelokimab in moderate-to-severe hidradenitis suppurativa, with VELA-2 missing its primary endpoint under the composite strategy.

MoonLake Immunotherapeutics announced its second quarter 2025 financial results, highlighting a robust cash position and pivotal progress in its Phase 3 VELA program for hidradenitis suppurativa.

MoonLake Immunotherapeutics announced that its shareholders elected all director nominees and approved all proposals, including the ratification of its independent auditor and executive compensation, at its 2025 Annual General Meeting.

MoonLake Immunotherapeutics announces Q1 2025 financial results, highlighting progress in sonelokimab development and securing a $500 million debt facility.

MoonLake Immunotherapeutics will host a Capital Markets Day event on April 29, 2025, to present its financial position, near-term clinical catalysts, and future strategic outlook.

MoonLake Immunotherapeutics has secured a non-dilutive term loan facility of up to $500 million from Hercules Capital to advance its clinical programs and prepare for the potential launch of sonelokimab.

MoonLake Immunotherapeutics announced its full year 2024 financial results, highlighting progress in Phase 3 clinical trials and a strong cash position.

MoonLake Immunotherapeutics reports the resignation of a board member and the approval of a long-term incentive program for key executives.

MoonLake Immunotherapeutics announced its Q3 2024 financial results, highlighting a strong cash position of $493.9 million and progress in its clinical programs for sonelokimab.

MoonLake Immunotherapeutics will post an investor presentation on its website for its September 11, 2024 Capital Markets Day event, detailing its financial position, near-term catalysts, and publication roadmap.

MoonLake Immunotherapeutics reported its second quarter 2024 financial results, highlighted progress in its clinical programs, and announced a Capital Markets Update for September 11.

MoonLake Immunotherapeutics has secured positive feedback from both the FDA and EMA for its Phase 3 program of sonelokimab in psoriatic arthritis, paving the way for trial initiation.

MoonLake Immunotherapeutics successfully held its 2024 Annual General Meeting, electing all director nominees and approving all proposals, including the ratification of the independent auditor and executive compensation.

MoonLake Immunotherapeutics reported positive clinical trial progress for its Nanobody sonelokimab and a strong cash position in its first quarter 2024 financial results.

MoonLake Immunotherapeutics reported significant improvements with their Nanobody sonelokimab in psoriatic arthritis and announced the commencement of Phase 3 trials in hidradenitis suppurativa.

MoonLake Immunotherapeutics announced positive financial results for 2023, highlighted by successful Phase 2 trial data for sonelokimab and a strong cash position, with an R&D day planned for March 10th.

MoonLake Immunotherapeutics has secured positive feedback from both the FDA and EMA regarding its Phase 3 program for sonelokimab in hidradenitis suppurativa, paving the way for a pivotal trial.